SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-048643
Filing Date
2022-02-22
Accepted
2022-02-22 16:45:25
Documents
12
Period of Report
2022-02-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d323690d8k.htm   iXBRL 8-K 21516
  Complete submission text file 0001193125-22-048643.txt   143118

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20220217.xsd EX-101.SCH 2905
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20220217_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20220217_pre.xml EX-101.PRE 11291
6 EXTRACTED XBRL INSTANCE DOCUMENT d323690d8k_htm.xml XML 3408
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 22658896
SIC: 2836 Biological Products, (No Diagnostic Substances)